Dina Ayman

Dina Ayman

Auto-generated profile, based on publicly available information

Dina Ayman

Faculty of Medicine, Beni-Suef University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in International Journal of Nursing Practice
Verified
Journal Article
Closed access
HSHusam Abu Suilik
Husam Abu Suilik
Jehad Feras AlSamhoriJehad Feras AlSamhori
Jehad Feras AlSamhori
Mohamed Tarek AbuelazmMohamed Tarek Abuelazm
Mohamed Tarek Abuelazm
YSYoussef Soliman
Youssef Soliman
DADina Ayman
Dina Ayman
Basel AbdelazeemBasel Abdelazeem
Basel Abdelazeem

23 December 2024 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
AAAhmed Mazen Amin
Ahmed Mazen Amin
HEHossam Elbenawi
Hossam Elbenawi
RORamez M. Odat
Ramez M. Odat
MEMohamed Elgebaly
Mohamed Elgebaly
AAAli Al-Shammari
Ali Al-Shammari
ADAndre D’Avila
Andre D’Avila

18 May 2026 in Baylor University Medical Center Proceedings
Verified
Journal Article
Open access
AAAhmed Mazen Amin
Ahmed Mazen Amin
WSWafaa Shehada
Wafaa Shehada
MEMohamed Elgebaly
Mohamed Elgebaly
DADina Ayman
Dina Ayman
MIMahmoud Mahmoud Ibrahim
Mahmoud Mahmoud Ibrahim
KFKevin Felpel
Kevin Felpel
Patients with hypertrophic cardiomyopathy (HCM) are generally restricted from exercising. We aimed to investigate the effects of exercise on cardiorespiratory fitness, cardiac structure, cardiac function, and clinical safety for patients with HCM. We performed a systematic review and meta-analysis by searching PubMed, Web of Science, Scopus, Embase, and CENTRAL up to April 2025. Dichotomous outcomes were pooled using risk ratios (RRs), while continuous outcomes were pooled using mean differences (MDs) or standardized mean differences (SMDs), all with 95% confidence intervals (CIs), using R version 4.3.1. With the inclusion of seven studies—three randomized controlled trials and four observational studies—our cohort comprised 9702 patients. Compared to the control group, exercise was significantly associated with increased cardiorespiratory fitness (peak oxygen consumption [peak VO2] (mL∙kg−1∙min−1) (MD: 1.78; 95% CI [0.98, 2.59]; P < 0.01) and VO2 at an anaerobic threshold (mL∙kg−1∙min−1) (MD: 1.27; 95% CI [0.34, 2.20]; P < 0.01), reduced body mass index (kg/m2) (MD: −0.67; 95% CI [−1.17, −0.18]; P < 0.01), reduced left ventricular wall thickness (mm) measured by echocardiography (MD: −0.56; 95% CI [−1.01, −0.11]; P = 0.01), increased quality of life physical factor (SMD: 0.66; 95% CI [0.34, 0.97]; P < 0.01), and decreased incidence of all-cause mortality (RR: 0.71; 95% CI [0.60, 0.85]; P < 0.01). This study suggests that structured exercise interventions are safe and associated with improvements in cardiorespiratory fitness, left ventricular wall thickness, body mass index, and quality of life physical factor in patients with HCM, without increasing the risk of arrhythmias. Although a lower mortality rate was observed, this finding was mainly driven by observational studies and should therefore be interpreted with caution. Larger randomized controlled trials are needed to confirm these findings.

31 March 2026 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
AAAli Al-Shammari
Ali Al-Shammari
NKNabeel Ibrahim Khaleel
Nabeel Ibrahim Khaleel
ASAhmed Sermed Al Sakini
Ahmed Sermed Al Sakini
ABAhmed Samy Badran
Ahmed Samy Badran
MHMohammed Tarek Hasan
Mohammed Tarek Hasan
RDRamesh Daggubati
Ramesh Daggubati
Percutaneous coronary intervention for distal left main bifurcation disease remains technically challenging owing to complex anatomy and high ischemic risk. Although multiple stenting techniques exist, the optimal approach is uncertain. Eligible strategies comprised provisional stenting, double-kissing (DK) crush, classic crush, minicrush, culotte, T-stenting, TAP, and nanocrush. The primary outcome was all-cause mortality. Secondary outcomes included cardiac death, myocardial infarction, stent thrombosis, target lesion revascularization, target vessel revascularization, and major adverse cardiovascular events (MACE). A frequentist random-effects network meta-analysis estimated hazard ratios (HRs) with 95% CIs, ranking treatments by P scores. Coherence was evaluated using node-splitting analyses. Individual-patient data were reconstructed from Kaplan-Meier curves for time-to-event outcomes. Fifteen studies (3794 patients) were included. DK crush consistently ranked highest for most efficacy and safety outcomes. Compared with classic crush, DK crush was associated with lower risks of myocardial infarction (HR, 0.40; 95% CI, 0.17-0.91), target lesion revascularization (HR, 0.35; 95% CI, 0.15-0.84), target vessel revascularization (HR, 0.30; 95% CI, 0.16-0.57), and MACE (HR, 0.46; 95% CI, 0.32-0.66). Culotte stenting was associated with a higher risk of stent thrombosis (HR, 3.30; 95% CI, 1.07-10.13). No significant differences were observed among strategies for all-cause or cardiac mortality (P > .05). Node-splitting analyses demonstrated no evidence of important local inconsistency. DK crush appears to provide the most effective and durable bifurcation strategy for distal left main percutaneous coronary intervention, reducing ischemia-driven revascularization and MACE. Findings support its preferential use in anatomically complex lesions, provided operator expertise and long-term follow-up are ensured.